Librela (bedinvetmab injection) is a monthly injectable monoclonal antibody, for which real-world drug experience data has ...

New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Dr. Ilana Etelzon Integrates CompuFlo® Epidural System into Practice Following Positive Clinical ExperienceROSELAND, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Inc. (NYSE: MLSS), a leading developer of ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

China Universal Asset Management Co. Ltd. boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

A new study using Mendelian randomization suggests that higher copper levels may increase fibromyalgia risk, while iron may ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...

Dr. Sterling Elliott, Clinical Pharmacist at Northwestern Medicine and Assistant Professor of Orthopedics at Feinberg School ...